Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity

Open access
Li, Ling, Knutsdottir, Hildur, Hui, Ken, Weiss, Matthew J., He, Jin, Philosophe, Benjamin, Cameron, Andrew M., Wolfgang, Christopher L., Pawlik, Timothy M., Ghiaur, Gabriel, Ewald, Andrew J., Mezey, Esteban, Bader, Joel S., Selaru, Florin M. · 2019 · JCI Insight

Abstract

Liver cancer is the fourth leading cause of cancer-related mortality and is distinguished by a relative paucity of chemotherapy options. It has been hypothesized that intratumor genetic heterogeneity may contribute to the high failure rate of chemotherapy. Here, we evaluated functional heterogeneity in a cohort of primary human liver cancer organoid lines. Each primary human liver cancer surgical specimen was used to generate multiple cancer organoid lines, obtained from distinct regions of the tumor. A total of 27 liver cancer lines were established and tested with 129 cancer drugs, generating 3,483 cell survival data points. We found a rich intratumor, functional (drug response) heterogeneity in our liver cancer patients. Furthermore, we established that the majority of drugs were either ineffective, or effective only in select organoid lines. In contrast, we found that a subset of drugs appeared pan-effective, displaying at least moderate activity in the majority of these cancer organoid lines. These drugs, which are FDA approved for indications other than liver cancers, deserve further consideration as either systemic or local therapeutics. Of note, molecular profiles, obtained for a reduced sample set, did not correlate with the drug response heterogeneity of liver cancer organoid lines. Taken together, these findings lay the foundation for in-depth studies of pan-effective drugs, as well as for functional personalized oncology approaches. Lastly, these functional studies demonstrate the utility of cancer organoid drug testing as part of a drug discovery pipeline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.121490

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 215

Metadata

Authors
Li, L., Knutsdottir, H., Hui, K., Weiss, M. J., He, J., Philosophe, B., Cameron, A. M., Wolfgang, C. L., Pawlik, T. M., Ghiaur, G., Ewald, A. J., Mezey, E., Bader, J. S., & Selaru, F. M.
Venue
JCI Insight
Published
2019-01-24
Volume
4
Issue
2
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2912813083
Cited by
215
References
13
FWCI
14.10
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. https://app.cochat.ai/papers/10.1172/jci.insight.121490
The paper
Li, L., Knutsdottir, H., Hui, K., Weiss, M. J., He, J., Philosophe, B., Cameron, A. M., Wolfgang, C. L., Pawlik, T. M., Ghiaur, G., Ewald, A. J., Mezey, E., Bader, J. S., & Selaru, F. M. (2019). Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight. https://doi.org/10.1172/jci.insight.121490

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.